Keep updated, see our News page!
THE WORD ABILITA DERIVES FROM LATIN AND MEANS “TO MAKE POSSIBLE”.
OUR COMPANY IS IN FACT FOCUSED ON DEVELOPING TECHNOLOGIES
TO ENABLE DRUG DISCOVERY EFFORTS TARGETING THE MOST CHALLENGING MEMBRANE PROTEINS LIKE
G PROTEIN-COUPLED RECEPTORS (GPCRs), ION CHANNELS, AND TRANSPORTERS.
WE ARE LEVERAGING OUR PROPRIETARY ENABLED MEMBRANE PROTEIN (EMP™) TECHNOLOGY PLATFORM
TO DRIVE THE DISCOVERY OF BIOLOGICS AND SMALL MOLECULES FOR OUR PARTNERS
AND TO FUEL OUR INTERNAL PIPELINE
TRANSFORMING THE FIELD OF MEMBRANE PROTEIN DRUG DISCOVERY
WHAT IS OUR MISSION:
ENABLING DRUG DISCOVERY FOR INTRACTABLE MEMBRANE PROTEIN TARGETS, INCLUDING
G PROTEIN-COUPLED RECEPTORS, ION CHANNELS AND TRANSPORTER
Antibody Discovery
Compound Screening
Crystallography
THE MARKET FOR DRUGS TARGETING MULTI-SPAN MEMBRANE PROTEINS:
0%
Of marketed drugs target membrane proteins
$0B
Annual global revenue for GPCRs alone
>0
Medically relevant MP targets identified in the human genome
0
Therapeutic antibody approved worldwide
<0%